IRWDIronwood Pharmaceuticals Inc
Earnings
When Ironwood Pharmaceuticals Inc reports, what it reported each quarter, and how the stock took the results.
60 quarters. Mar 31, 2010 to Sep 30, 2026. USD.
Next results · Q4 2026Projected
Feb 24, before the open
Wed, Feb 24, 2027in 99 days
Projected from its last 8 releases. The company has not named the day yet.
- Quarter
- Q4 2026 · Ends about Dec 31, 2026
- 10-K window
- Feb 16 – Mar 1
Read against Q4 2025
The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.
- Revenue
- $47.71M
- Revenue, change from a year earlier: Q3 2026 +9.0%, Q2 2026 +32.6%, Q1 2026 +158.9%, Q4 2025 −47.3%
- Net income
- -$2.28M
- Net income, change from a year earlier: Q3 2026 +49.3%, Q2 2026 +117.3%, Q1 2026 n/m, Q4 2025 n/m
- EPS
- -$0.01
- EPS, change from a year earlier: Q3 2026 +56.5%, Q2 2026 +121.4%, Q1 2026 n/m, Q4 2025 n/m
Latest results
- Revenue
- $133.04M
- +9.0%
- Net income
- $59.84M
- +49.3%
- EPS
- $0.36
- +56.5%
- Revenue
- $113.04M
- +32.6%
- Net income
- $51.29M
- +117.3%
- EPS
- $0.31
- +121.4%
- Revenue
- $106.51M
- +158.9%
- Net income
- $40.77M
- N/M
- EPS
- $0.24
- N/M
- Revenue
- $47.71M
- −47.3%
- Net income
- -$2.28M
- N/M
- EPS
- -$0.01
- N/M
All quarters
| Period | Ended | Announced | Filed | Lag | Form | Revenue | Δ yoy | EPS dil. | Move | Source trail |
|---|---|---|---|---|---|---|---|---|---|---|
| FY 2026 | ||||||||||
| Q3 2026 | Sep 30, 2026 | Nov 5, 2026 · pre-market | Nov 5, 2026 | 36 d | 10-Q | $133.04M | +9.0% | $0.36 | +6.5% | |
| Q2 2026 | Jun 30, 2026 | Aug 6, 2026 · pre-market | Aug 6, 2026 | 37 d | 10-Q | $113.04M | +32.6% | $0.31 | +3.1% | |
| Q1 2026 | Mar 31, 2026 | May 7, 2026 · pre-market | May 7, 2026 | 37 d | 10-Q | $106.51M | +158.9% | $0.24 | 14.1% | |
| FY 2025 | ||||||||||
| Q4 2025 | Dec 31, 2025 | Feb 25, 2026 · pre-market | Feb 26, 2026 | 57 d | 10-K | $47.71M | −47.3% | -$0.01 | 11.1% | |
| Q3 2025 | Sep 30, 2025 | Nov 10, 2025 · pre-market | Nov 10, 2025 | 41 d | 10-Q | $122.06M | +33.3% | $0.23 | +32.7% | |
| Q2 2025 | Jun 30, 2025 | Aug 7, 2025 · pre-market | Aug 11, 2025 | 42 d | 10-Q | $85.24M | −9.7% | $0.14 | +8.5% | |
| Q1 2025 | Mar 31, 2025 | May 7, 2025 · pre-market | May 12, 2025 | 42 d | 10-Q | $41.14M | −45.1% | -$0.23 | 14.6% | |
| FY 2024 | ||||||||||
| Q4 2024 | Dec 31, 2024 | Feb 27, 2025 · pre-market | Mar 31, 2025 | 90 d | 10-K | $90.55M | −23.0% | $0.01 | 5.3% | |
| Q3 2024 | Sep 30, 2024 | Nov 7, 2024 · pre-market | Nov 7, 2024 | 38 d | 10-Q | $91.59M | −19.5% | $0.02 | 7.7% | |
| Q2 2024 | Jun 30, 2024 | Aug 8, 2024 · pre-market | Aug 8, 2024 | 39 d | 10-Q | $94.40M | −12.1% | -$0.01 | — | |
| Q1 2024 | Mar 31, 2024 | May 9, 2024 · pre-market | May 9, 2024 | 39 d | 10-Q | $74.88M | −28.0% | -$0.03 | 17.6% | |
| FY 2023 | ||||||||||
| Q4 2023 | Dec 31, 2023 | Feb 15, 2024 · pre-market | Feb 16, 2024 | 47 d | 10-K | $117.55M | +9.7% | -$0.01 | — | |
| Q3 2023 | Sep 30, 2023 | Nov 9, 2023 · pre-market | Nov 9, 2023 | 40 d | 10-Q | $113.74M | +4.7% | $0.09 | +3.1% | |
| Q2 2023 | Jun 30, 2023 | Aug 8, 2023 · pre-market | Aug 9, 2023 | 40 d | 10-Q | $107.38M | — | -$6.84 | — | |
| Q1 2023 | Mar 31, 2023 | May 4, 2023 · pre-market | May 4, 2023 | 34 d | 10-Q | $104.06M | — | $0.25 | +2.3% | |
| FY 2022 | ||||||||||
| Q4 2022 | Dec 31, 2022 | Feb 16, 2023 · pre-market | Feb 16, 2023 | 47 d | 10-K | $107.20M | — | $0.27 | +1.8% | |
| Q3 2022 | Sep 30, 2022 | Nov 3, 2022 · pre-market | Nov 3, 2022 | 34 d | 10-Q | $108.64M | — | $0.28 | +3.9% | |
| FY 2021 | ||||||||||
| Q4 2021 | Mar 31, 2022 | May 5, 2022 · pre-market | — | — | — | $97.53M | +9.8% | $0.21 | — | |
| Q1 2021 | Jun 30, 2021 | Aug 5, 2021 · pre-market | Aug 5, 2021 | 36 d | 10-Q | $104.03M | — | $2.39 | +2.7% | |
| FY 2020 | ||||||||||
| Q4 2020 | Mar 31, 2021 | May 6, 2021 · pre-market | — | — | — | $88.85M | — | $0.25 | — | |
| FY 2019 | ||||||||||
| Q4 2019 | Dec 31, 2019 | Feb 13, 2020 · pre-market | Feb 13, 2020 | 44 d | 10-K | $126.30M | −3.4% | $0.30 | — | |
| Q3 2019 | Sep 30, 2019 | Oct 31, 2019 · pre-market | Oct 31, 2019 | 31 d | 10-Q | $131.17M | +99.7% | $0.13 | +6.5% | |
| Q2 2019 | Jun 30, 2019 | Jul 30, 2019 · after-hours | Jul 30, 2019 | 30 d | 10-Q | $102.22M | +26.0% | $0.08 | 1.0% | |
| Q1 2019 | Mar 31, 2019 | May 2, 2019 · pre-market | May 2, 2019 | 32 d | 10-Q | $68.73M | −0.6% | -$0.38 | 9.9% | |
| FY 2018 | ||||||||||
| Q4 2018 | Dec 31, 2018 | Feb 13, 2019 · pre-market | Feb 25, 2019 | 56 d | 10-K | $130.69M | +38.7% | -$0.10 | +15.1% | |
| Q3 2018 | Sep 30, 2018 | — | Nov 6, 2018 | 37 d | 10-Q | $65.69M | −24.3% | -$1.14 | 12.0% | |
| Q2 2018 | Jun 30, 2018 | — | Aug 6, 2018 | 37 d | 10-Q | $81.11M | +24.6% | -$0.32 | +3.3% | |
| Q1 2018 | Mar 31, 2018 | — | May 4, 2018 | 34 d | 10-Q | $69.16M | +32.6% | -$0.29 | 2.1% | |
| FY 2017 | ||||||||||
| Q4 2017 | Dec 31, 2017 | — | Feb 22, 2018 | 53 d | 10-K | $94.21M | +7.7% | $0.08 | 1.0% | |
| Q3 2017 | Sep 30, 2017 | — | Nov 2, 2017 | 33 d | 10-Q | $86.83M | +31.3% | -$0.22 | +4.6% | |
| Q2 2017 | Jun 30, 2017 | — | Aug 3, 2017 | 34 d | 10-Q | $65.08M | +19.7% | -$0.30 | 12.8% | |
| Q1 2017 | Mar 31, 2017 | — | May 8, 2017 | 38 d | 10-Q | $52.17M | −21.0% | -$0.36 | — | |
| FY 2016 | ||||||||||
| Q4 2016 | Dec 31, 2016 | — | Feb 22, 2017 | 53 d | 10-K | $87.46M | +64.1% | -$0.09 | 0.4% | |
| Q3 2016 | Sep 30, 2016 | — | Nov 7, 2016 | 38 d | 10-Q | $66.11M | +67.1% | -$0.23 | +2.9% | |
| Q2 2016 | Jun 30, 2016 | — | Aug 8, 2016 | 39 d | 10-Q | $54.35M | +95.9% | -$0.15 | +0.5% | |
| Q1 2016 | Mar 31, 2016 | — | May 10, 2016 | 40 d | 10-Q | $66.04M | +128.3% | -$0.09 | 2.8% | |
| FY 2015 | ||||||||||
| Q4 2015 | Dec 31, 2015 | — | Feb 19, 2016 | 50 d | 10-K | $53.31M | +40.0% | -$0.09 | +2.8% | |
| Q3 2015 | Sep 30, 2015 | — | Nov 5, 2015 | 36 d | 10-Q | $39.57M | +133.9% | -$0.33 | +3.1% | |
| Q2 2015 | Jun 30, 2015 | — | Aug 7, 2015 | 38 d | 10-Q | $27.74M | +305.6% | -$0.34 | +2.3% | |
| Q1 2015 | Mar 31, 2015 | — | May 6, 2015 | 36 d | 10-Q | $28.93M | +98.1% | -$0.24 | 1.9% | |
| FY 2014 | ||||||||||
| Q4 2014 | Dec 31, 2014 | — | Feb 18, 2015 | 49 d | 10-K | $38.07M | +656.8% | -$0.27 | +2.4% | |
| Q3 2014 | Sep 30, 2014 | — | Nov 5, 2014 | 36 d | 10-Q | $16.92M | +243.0% | -$0.30 | +9.9% | |
| Q2 2014 | Jun 30, 2014 | — | Aug 5, 2014 | 36 d | 10-Q | $6.84M | −29.2% | -$0.44 | — | |
| Q1 2014 | Mar 31, 2014 | — | Apr 29, 2014 | 29 d | 10-Q | $14.61M | +348.7% | -$0.38 | — | |
| FY 2013 | ||||||||||
| Q4 2013 | Dec 31, 2013 | — | Feb 7, 2014 | 38 d | 10-K | $5.03M | −81.4% | -$0.43 | — | |
| Q3 2013 | Sep 30, 2013 | — | Oct 28, 2013 | 28 d | 10-Q | $4.93M | −94.9% | -$0.51 | — | |
| Q2 2013 | Jun 30, 2013 | — | Aug 8, 2013 | 39 d | 10-Q | $9.66M | −33.8% | -$0.57 | — | |
| Q1 2013 | Mar 31, 2013 | — | Apr 23, 2013 | 23 d | 10-Q | $3.26M | −73.4% | -$0.87 | — | |
| FY 2012 | ||||||||||
| Q4 2012 | Dec 31, 2012 | — | Feb 21, 2013 | 52 d | 10-K | $26.98M | −16.1% | -$0.41 | — | |
| Q3 2012 | Sep 30, 2012 | — | Nov 6, 2012 | 37 d | 10-Q | $96.41M | +689.1% | $0.42 | — | |
| Q2 2012 | Jun 30, 2012 | — | Aug 7, 2012 | 38 d | 10-Q | $14.60M | +29.7% | -$0.38 | — | |
| Q1 2012 | Mar 31, 2012 | — | May 10, 2012 | 40 d | 10-Q | $12.25M | +19.6% | -$0.34 | — | |
| FY 2011 | ||||||||||
| Q4 2011 | Dec 31, 2011 | — | Feb 29, 2012 | 60 d | 10-K | $32.15M | +91.7% | -$0.07 | — | |
| Q3 2011 | Sep 30, 2011 | — | Nov 9, 2011 | 40 d | 10-Q | $12.22M | +34.9% | -$0.21 | — | |
| Q2 2011 | Jun 30, 2011 | — | Aug 12, 2011 | 43 d | 10-Q | $11.26M | +22.6% | -$0.19 | — | |
| Q1 2011 | Mar 31, 2011 | — | — | — | — | $10.24M | +15.8% | -$0.19 | — | |
| FY 2010 | ||||||||||
| Q4 2010 | Dec 31, 2010 | — | — | — | — | $16.77M | — | -$0.12 | — | |
| Q3 2010 | Sep 30, 2010 | — | — | — | — | $9.06M | — | -$0.08 | — | |
| Q2 2010 | Jun 30, 2010 | — | — | — | — | $9.19M | — | -$0.18 | — | |
| Q1 2010 | Mar 31, 2010 | — | — | — | — | $8.84M | — | -$0.25 | — | |
Earlier years, FY 2010 to FY 2023The latest three years
Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Source filings
Provenance
ProvenanceData status and checks
Ironwood Pharmaceuticals Inc · CIK 1446847 · Engraved from SEC EDGAR